ω-3 脂肪酸与心血管疾病危险因素：随机临床试验的更新系统综述。

Omega 3 fatty acids in cardiovascular disease risk factors: An updated systematic review of randomised clinical trials.

机构信息

Department of Biochemistry and Molecular Biology Molecular II, Institute of Nutrition and Food Technology, Biomedical Research Centre, University of Granada, Granada, Spain.

Department of Biochemistry and Molecular Biology Molecular II, Institute of Nutrition and Food Technology, Biomedical Research Centre, University of Granada, Granada, Spain; Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición, CIBEROBN, Madrid, Spain.

出版信息

Clin Nutr. 2018 Feb;37(1):72-77. doi: 10.1016/j.clnu.2017.05.015. Epub 2017 May 19.

DOI:10.1016/j.clnu.2017.05.015

PMID:28601400

Abstract

Several studies and reviews regarding the supplementation of omega-3 LC-PUFAs have been developed during the last years. Indeed, the evidence states that high doses omega-3 LC-PUFAs produce a small but significant decrease in blood pressure in older and hypertensive subjects. Due to the increasing interest in the benefits of LC-PUFAs, we aimed to evaluate the scientific evidence provided in the past five years (2012-2016) on the effects of the intake of omega-3 LC-PUFAs on cardiovascular risk factors such as inflammation and oxidative stress, through a systematic review in PubMed database. Twenty-eight articles were related to cardiovascular disease (CVD) and are included in this systematic review. The studies included healthy subjects and CVD patients; we included the number of subjects, type of study, type and doses of omega-3 LC-PUFAs, primary outcomes, and results. The use of omega-3 LC-PUFAs for ameliorating CVD risk factors can be recommended. However, the administration of omega-3 does not seem to show any benefit for the management of CVD or associated complications.

摘要

近年来，已经有多项关于ω-3 LC-PUFA 补充剂的研究和综述。事实上，有证据表明，高剂量的 ω-3 LC-PUFA 可使老年和高血压患者的血压略有但显著降低。由于人们对 LC-PUFA 的益处越来越感兴趣，我们旨在通过在 PubMed 数据库中进行系统评价，评估过去五年（2012-2016 年）内有关摄入 ω-3 LC-PUFA 对心血管危险因素（如炎症和氧化应激）影响的科学证据。有 28 篇文章与心血管疾病（CVD）相关，并包含在本系统评价中。这些研究包括健康受试者和 CVD 患者；我们纳入了研究对象的数量、研究类型、ω-3 LC-PUFA 的类型和剂量、主要结局和结果。可以推荐使用 ω-3 LC-PUFA 来改善 CVD 的危险因素。然而，ω-3 的使用似乎对 CVD 或相关并发症的管理没有任何益处。